| Metric | Value | Detail |
|---|---|---|
| Revenue | $62.6B | -1.6% YoY |
| Net income | $7.8B | 12.5% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | n/a | Operating income / revenue |
| Return on equity | 9% | Net income / equity |
| Return on assets | 4% | Net income / assets |
| Revenue growth (YoY) | -1.6% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | -14.8% | Compound annual |
| Diluted EPS | $1.37 | FY2025 |
| Debt-to-equity | 0.71 | Long-term debt / equity |
| Current ratio | 1.16 | Current assets / liabilities |
| Cash & equivalents | $1.2B | Balance sheet |
| Total assets | $208.2B | FY2025 year-end |
| Shareholders’ equity | $86.8B | FY2025 year-end |
| Share price | $24.17 | Delayed · 2026-07-10 |
| Market cap | $137.8B | Price × shares outstanding |
| P/E ratio | 17.6 | Market cap / net income |
| P/S ratio | 2.2 | Market cap / revenue |
| Dividend yield | 7.12% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
Pfizer Inc. (PFE) stock fundamentals
Pfizer Inc. (PFE) reported $62.6B in revenue and $7.8B in net income in fiscal 2025, a 12.5% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $137.8B at a delayed share price. It scores 34/100 on WealthyBud's Investor Score, ranking #88 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$62.6B
▼ -1.6% YoY
Net income
$7.8B
12.5% net margin
Market cap
$137.8B
Price $24.17 · delayed
P/E ratio
17.6
Price / earnings
Return on equity
9%
Net income / equity
Investor Score
34/100
#88 of 100 covered
Pfizer Inc. fundamentals at a glance
The table summarizes Pfizer Inc.'s key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is Pfizer Inc.?
Pfizer Inc. runs a 12.5% net margin and n/a gross margin in fiscal 2025, turning $62.6B of revenue into $7.8B of profit. Return on equity is 9% and return on assets 4%.
Is Pfizer Inc. growing?
Pfizer Inc.'s revenue changed -1.6% in fiscal 2025 and compounded at -14.8% a year over three years, reaching $62.6B. Diluted earnings per share were $1.37 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $81.3B | n/a |
| 2022 | $101.2B | +24.5% |
| 2023 | $59.6B | -41.1% |
| 2024 | $63.6B | +6.8% |
| 2025 | $62.6B | -1.6% |
How is Pfizer Inc. valued?
Pfizer Inc. carries a market capitalization of $137.8B at a delayed share price of $24.17, trading at a 17.6 price-to-earnings ratio and 2.2 price-to-sales with a 7.12% dividend yield. Its Value subscore is 85/100 across the covered universe.
How financially healthy is Pfizer Inc.?
Pfizer Inc. ended fiscal 2025 with $1.2B in cash, a debt-to-equity ratio of 0.71 and a current ratio of 1.16. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is Pfizer Inc.'s Investor Score?
Pfizer Inc. scores 34/100 on WealthyBud's Investor Score, #88 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
34/100
#88 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
Pfizer Inc. (PFE) stock FAQ
How much revenue does Pfizer Inc. make?
Pfizer Inc. (PFE) reported $62.6B in revenue in fiscal 2025, -1.6% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at -14.8% a year.
Is Pfizer Inc. profitable?
Yes. Pfizer Inc. earned $7.8B in net income in fiscal 2025, a 12.5% net margin. Its return on equity was 9% and return on assets 4%, based on figures from its latest 10-K.
How fast is Pfizer Inc. growing?
Pfizer Inc.'s revenue changed -1.6% year over year in fiscal 2025 and compounded at -14.8% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 15/100 versus the covered universe.
What is Pfizer Inc.'s market cap and P/E ratio?
Pfizer Inc. has a market capitalization of $137.8B at a delayed share price of $24.17, trading at a price-to-earnings ratio of 17.6 and price-to-sales of 2.2. Its dividend yield is 7.12%. Prices are delayed and illustrative.
What is Pfizer Inc.'s WealthyBud Investor Score?
Pfizer Inc. scores 34/100, ranking #88 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (15), profitability (30), returns on capital (14), balance-sheet strength (50) and value (85). It is a research opinion, not investment advice.
Where does this Pfizer Inc. financial data come from?
Fundamentals come from Pfizer Inc.'s annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from Pfizer Inc.’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.